Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOTO: 5/2 Intermittent Treatment Schedule for HIV
NCT00414635Phase 4Completed
- Sponsor
- Community Research Initiative of New England
- Start
- Aug 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of efavirenz, tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Community Research Initiative of New England. Primary endpoint: Percentage of Participants Who Maintained Virologic Suppression (Less Than 50 RNA Cps/ml) at 24 weeks. Started Aug 2006; status: completed.
02
Drugs
efavirenztenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00414635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00414635.